Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Canagliflozin/Metformin FDC vs Co-administration
NCT02221180Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2014
- Primary completion
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of canagliflozin + metformin in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Plasma Concentration of Metformin and Plasma Concentration of Canagliflozin. Started Aug 2014; status: completed.
02
Drugs
canagliflozin + metformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02221180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02221180.